Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

NCT05918328 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

610

Enrollment

OTHER_GOV

Sponsor class

Conditions

Breast Cancer
HER2-positive Breast Cancer

Interventions

DRUG: Albumin paclitaxel+trastuzumab+pyrrolitinib
DRUG: Docetaxel+Carboplatin+trastuzumab+Parstuzumab

Sponsor

Henan Cancer Hospital